Antibody–Drug Conjugates in Uro-Oncology Dawid SigorskiPaweł RóżanowskiKatarzyna Wiktorska Review Article 14 May 2022 Pages: 203 - 221
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review Thomas D. McLeanSerena DuchiClaudia Di Bella Review Article Open access 21 April 2022 Pages: 223 - 252
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents Daniel V. AraujoBruno UchoaMarc Oliva Review Article 10 June 2022 Pages: 253 - 270
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study Abdulazeez SalawuAaron R. HansenAlbiruni R. Abdul Razak Original Research Article 30 May 2022 Pages: 271 - 281
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study Tanya TrippettHelen ToledanoBirgit Geoerger Original Research Article Open access 17 June 2022 Pages: 283 - 293
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan Yen-Hsiang HuangKuo-Hsuan HsuGee-Chen Chang Original Research Article Open access 23 April 2022 Pages: 295 - 306
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era Hiroki IshiharaYuki NemotoToshio Takagi Original Research Article 23 April 2022 Pages: 307 - 319
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer Andrew J. KlinkAbhishek KavatiRuth Antoine Original Research Article Open access 18 June 2022 Pages: 321 - 328
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor Laura C. KennedyJun LuVijayakrishna K. Gadi Original Research Article 13 June 2022 Pages: 329 - 341
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy Takuro MizukamiMasaki TakahashiTakako Eguchi Nakajima Original Research Article 07 May 2022 Pages: 343 - 353
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors Joan R. E. ChooYi-Hua JanSoo Chin Lee Original Research Article Open access 14 June 2022 Pages: 355 - 368
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC James E. Frampton Adis Drug Evaluation 17 June 2022 Pages: 369 - 376
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Toshio ShimizuYasutoshi KubokiKyu-pyo Kim Correction Open access 12 April 2022 Pages: 377 - 377
Correction to: MYL-1402O: A Bevacizumab Biosimilar Arnold Lee Correction Open access 18 April 2022 Pages: 379 - 379
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer Lesley J. Scott Correction Open access 05 May 2022 Pages: 381 - 381